Press Releases

Filters
October 9, 2019

A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…

Read more
September 30, 2019

Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients

Read more
September 3, 2019

Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients

Read more
July 9, 2019

Debiopharm and BIOASTER join forces to expand research to combat infectious diseases

Read more
June 12, 2019

Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years

Read more
June 3, 2019

Caris Life Sciences Partners with Debiopharm International SA to Develop Companion Diagnostic for Detection of Rare FGFR Fusions Using Novel…

Read more
May 21, 2019

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Read more
May 14, 2019

Debiopharm awarded $2.1 million from CARB-X in the fight against a highly resistant nosocomial-pneumonia causing superbug

Read more
April 1, 2019

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Read more